Nestlé is betting $525M on a bid to pioneer world's first microbiome drug

Nicole DeFeudis

Editor

After fighting a years-long uphill battle with its oral microbiome candidate SER-109, Seres Therapeutics finally got the Phase III results it was looking for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nestlé is betting $525M on a bid to pioneer world's first microbiome drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Nestlé is bet­ting $525M on a bid to pi­o­neer world's first mi­cro­bio­me drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Nestlé is betting $525M on a bid to pioneer world's first microbiome drug

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence